Estrella Immunopharma, Inc. (ESLA) stock
ESLANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as ESLAW
Financials through Q1 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.33−0.05 (-12.74%)
Close on Nov 17, 2026Market cap $14.42MP/E –Yield –
Estrella Immunopharma cash
Cash and short-term investments held at the end of each period.
Estrella Immunopharma's cash was $100.00K at Jun 30, 2026. For fiscal 2024 it was $4.17M, up 769.8% from the year before.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Jun 30, 2024 | $4.17M | +769.8% |
| FY2021 | Dec 31, 2021 | $478.87K | – |
Quarterly cash
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2026CQ3 2025 | Jun 30, 2026 | $100.00K | -99.5% |
| Q4 FY2024CQ2 2024 | Jun 30, 2024 | $4.17M | +769.8% |
| Q3 FY2024CQ1 2024 | Mar 31, 2024 | $4.73M | +512.2% |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | $9.05M | +82002.2% |
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | $22.14M | +52513.1% |
| Q4 FY2021CQ4 2021 | Dec 31, 2021 | $478.87K | – |
| Q3 FY2021CQ3 2021 | Sep 30, 2021 | $772.17K | – |
| Q2 FY2021CQ2 2021 | Jun 30, 2021 | $11.02K | – |
| Q1 FY2021CQ1 2021 | Mar 31, 2021 | $42.08K | – |
See a number that looks wrong?